1 / 2

D’après Rosell R et al., abstr. O19.02 actualisé

Thérapies ciblées. Erlotinib avec ou sans dalotuzumab Résultats. D’après Rosell R et al., abstr. O19.02 actualisé. Thérapies ciblées. Erlotinib avec ou sans dalotuzumab Survie sans progression. 100. 80. 60. SSP (%). Dalotuzumab + erlotinib. 40. Erlotinib. 20. 0. 0. 2. 4. 6. 8.

kapono
Download Presentation

D’après Rosell R et al., abstr. O19.02 actualisé

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thérapies ciblées Erlotinib avec ou sans dalotuzumabRésultats D’après Rosell R et al., abstr. O19.02 actualisé

  2. Thérapies ciblées Erlotinib avec ou sans dalotuzumabSurvie sans progression 100 80 60 SSP (%) Dalotuzumab + erlotinib 40 Erlotinib 20 0 0 2 4 6 8 10 12 Mois D’après Rosell R et al., abstr. O19.02 actualisé

More Related